Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This will be a phase II single-arm clinical trial. The purpose of this study is to determine
the feasibility of deescalating chemoradiation treatment based onmid-treatment tumor
response. The primary objective of this study is to evaluate progression-free survival at 2
years.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health